Carboplatin plus paclitaxel improves quality of life in ovarian cancer
the ONA take:
There is no significant quality of life advantage of cisplatin plus topotecan compared with paclitaxel plus carboplatin in the treatment of women with newly diagnosed ovarian cancer, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
A recent phase 3 study in women with newly diagnosed stage 2B or greater ovarian cancer found that cisplatin plus topotecan followed by carboplatin plus paclitaxel had a significantly lower response rate vs paclitaxel plus carboplatin. The study also demonstrated no significant difference in progression-free survival at 43 months of follow-up.
In this analysis, researchers sought to evaluate the impact of each regimen on quality of life. Results showed that global quality of life, physical symptoms, fatigue, and various function scores significantly improved in both groups, but there was no significant difference between the arms. Researchers found that nausea and vomiting improve more with paclitaxel plus carboplatin during and after treatment.
The findings of this analysis combined with the efficacy results of the phase 3 trial suggest that carboplatin plus paclitaxel should continue to be the standard of care for patients with newly diagnosed ovarian cancer.
There is no significant quality of life advantage of cisplatin plus topotecan in treatment of women with newly diagnosed ovarian cancer.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Eischens Yoga May Benefit Men Undergoing Radiation Therapy for Prostate Cancer
- Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer
- New Criteria for Appropriate Use of Bone Scintigraphy to Diagnose and Manage Prostate and Breast Cancer
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|